Aurobindo Pharma Ltd's Q4FY25 Quarterly Results

Result Summary

• Aurobindo Pharma Ltd reported a 5.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 16.8%.
• Its expenses for the quarter were down by 8.5% QoQ and up 8.2% YoY.
• The net profit increased 7.3% QoQ and increased 79.4% YoY.
• The earnings per share (EPS) of Aurobindo Pharma Ltd stood at 15.5 during Q4FY25.

Financial Statments for Q4FY25

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aurobindo Pharma Ltd is a prominent pharmaceutical company based in India, known for its extensive portfolio of generic pharmaceuticals and active pharmaceutical ingredients. The company operates within the healthcare and pharmaceutical industry, producing a range of products that include formulations for antibiotics, antiretrovirals, and other therapeutic segments. Aurobindo Pharma is recognized for its global reach, with a substantial presence in markets such as the United States, Europe, and emerging markets. As of the latest reports, there are no specific major developments available within the context of this analysis.

Revenue

In the fourth quarter of the fiscal year 2025 (Q4FY25), Aurobindo Pharma Ltd reported a total income of ₹7715.77 crores, which represents a 16.8% increase compared to the same quarter in the previous year (Q4FY24), where the total income was ₹6607.87 crores. However, on a quarter-over-quarter basis, there was a decline of 5.2% compared to the third quarter of FY25 (Q3FY25), where the total income stood at ₹8135.81 crores. This decrease in total income from the previous quarter is notable, although the year-over-year growth indicates an overall upward trend in revenue generation.

Profitability

Aurobindo Pharma's profitability metrics for Q4FY25 reveal a Profit Before Tax (PBT) of ₹1242.56 crores, marking a substantial year-over-year increase of 68.8% from ₹735.92 crores in Q4FY24. On a quarter-over-quarter basis, PBT improved by 3.7% from Q3FY25's ₹1198.26 crores. The company reported a Profit After Tax (PAT) of ₹907.35 crores for Q4FY25, a significant improvement of 79.4% from the ₹505.91 crores recorded in the same quarter of the previous year. QoQ, the PAT increased by 7.3% from Q3FY25's ₹845.57 crores. The Earnings Per Share (EPS) for Q4FY25 was ₹15.50, which is a notable rise from ₹8.60 in Q4FY24, representing an increase of 80.2% YoY. The EPS also grew by 6.2% QoQ from Q3FY25's ₹14.60.

Operating Metrics

Total expenses for Aurobindo Pharma in Q4FY25 were reported at ₹6351.10 crores, reflecting an 8.2% increase compared to the same quarter in the previous year, where expenses were ₹5871.95 crores. However, compared to Q3FY25, total expenses decreased by 8.5% from ₹6937.55 crores. The tax expense for Q4FY25 was ₹322.55 crores, which is a 43.9% increase from ₹224.15 crores in Q4FY24, but a decrease of 9.0% from the ₹354.28 crores reported in Q3FY25. These operating metrics indicate shifts in cost management and tax expenses on both a quarterly and annual basis.